BRÈVE publiée le 11/12/2025 à 23:05, il y a 6 mois 11 jours Xenetic Biosciences ajourne son assemblée générale annuelle des actionnaires de 2025. Instructions De Vote Quorum Biosciences Xénétiques Assemblée Générale Des Actionnaires Ajournement De 2025
BRÈVE publiée le 11/12/2025 à 23:05, il y a 6 mois 11 jours Xenetic Biosciences Adjourns 2025 Annual Stockholders Meeting Xenetic Biosciences Stockholders Meeting Voting Instructions Quorum 2025 Adjournment
COMMUNIQUÉ DE PRESSE publié le 11/12/2025 à 23:00, il y a 6 mois 11 jours Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting Xenetic Biosciences, Inc. adjourns 2025 Annual Meeting of Stockholders due to lack of quorum. Stockholders urged to vote before reconvened meeting on January 8, 2026 Xenetic Biosciences Stockholders Quorum Proxy Vote 2025 Annual Meeting
BRÈVE publiée le 19/11/2025 à 14:50, il y a 7 mois 3 jours Xenetic Biosciences étend sa collaboration avec Scripps Research Biopharmaceutique Traitement Du Cancer DNase I Thérapie CAR-T Recherche Scripps
BRÈVE publiée le 19/11/2025 à 14:50, il y a 7 mois 3 jours Xenetic Biosciences Extends Collaboration with Scripps Research Cancer Treatment Biopharmaceutical DNase I CAR-T Therapy Scripps Research
COMMUNIQUÉ DE PRESSE publié le 19/11/2025 à 14:45, il y a 7 mois 3 jours Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform Xenetic Biosciences extends collaboration with Scripps Research to advance DNase-based immuno-oncology treatment for cancers Xenetic Biosciences Immuno-oncology DNase I CAR-T Therapy Scripps Research
BRÈVE publiée le 13/11/2025 à 14:50, il y a 7 mois 9 jours Xenetic Biosciences publie ses résultats financiers du troisième trimestre 2025 Résultats Financiers Essais Cliniques Augmentation Des Revenus Technologie DNase Carcinome Pancréatique
BRÈVE publiée le 13/11/2025 à 14:50, il y a 7 mois 9 jours Xenetic Biosciences Reports Q3 2025 Financial Results Financial Results Revenue Increase Clinical Trials Pancreatic Carcinoma DNase Technology
COMMUNIQUÉ DE PRESSE publié le 13/11/2025 à 14:45, il y a 7 mois 9 jours Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q3 2025 financial results, focuses on DNase-based technology for cancer treatment. Secured $3.9 million from offering, advancing collaborations Xenetic Biosciences Cancer Treatment Collaborations DNase Technology Q3 2025 Financial Results
BRÈVE publiée le 10/10/2025 à 15:35, il y a 8 mois 12 jours Xenetic Biosciences Announces $4.5 Million Stock Offering Xenetic Biosciences Biopharmaceutical Immuno-oncology Stock Offering Canaccord Genuity
Publié le 22/06/2026 à 18:00, il y a 5 heures 46 minutes GUILLEMOT CORPORATION : DECES DE M. CLAUDE GUILLEMOT, Président du Groupe GUILLEMOT CORPORATION
Publié le 22/06/2026 à 23:25, il y a 21 minutes Infield Minerals Announces Intention to Issue Shares for Kings Canyon Gold Property Option Payment
Publié le 22/06/2026 à 23:05, il y a 41 minutes Gamma Resources Settles Remaining Balance of Outstanding Debt
Publié le 22/06/2026 à 21:05, il y a 2 heures 41 minutes RUM Announces Voting Results From Annual General Meeting of Shareholders
Publié le 22/06/2026 à 19:45, il y a 4 heures 1 minute Trans Canada Gold Appoints Paradigm Drilling Ltd. for Drilling at the Harrison Lake District Scale Gold Project, Drilling to Commence Shortly
Publié le 22/06/2026 à 15:58, il y a 7 heures 48 minutes Metallic Minerals Closes Upsized C$10.3 Million Bought Deal LIFE Private Placement
Publié le 22/06/2026 à 21:07, il y a 2 heures 39 minutes EQS-Adhoc: RWE Aktiengesellschaft: RWE sets placement price for shares from capital measure and raises gross proceeds of 4 billion EUR
Publié le 22/06/2026 à 20:50, il y a 2 heures 56 minutes Ethlabs, Founded by Former Ethereum Foundation Contributors and Funded by Bitmine, Sharplink and Joe Lubin, Launches to Accelerate Ethereum's Institutional Supercycle
Publié le 22/06/2026 à 20:32, il y a 3 heures 13 minutes EQS-Adhoc: Deutsche Konsum Real Estate AG: Daniel Löhken appointed Chief Executive Officer of the Company and Dr Kai Gregor Klinger appointed new Chairman of the Supervisory Board
Publié le 22/06/2026 à 19:27, il y a 4 heures 19 minutes Fuller, Smith & Turner PLC: Director/PDMR Shareholdings
Publié le 22/06/2026 à 18:54, il y a 4 heures 51 minutes EQS-Adhoc: Brenntag SE publishes preliminary operating EBITDA for the second quarter of 2026 and increases its guidance for the financial year 2026
